A multicenter double-blind randomized placebo-controlled trial to evaluate

Recruiting

18 years - 100 years

All

Phase 3

3 participants needed

1 Location

Brief description of study

The purpose of this study is to find out if the investigational drug, apraglutide and investigational drug , is able to reduce the volume per week of PS required in adults with short bowel syndrome and intestinal failure.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: short bowel syndrome,intestinal failure
Age: 18 years - 100 years
Gender: All

Male and female patients aged ≥18 years have short bowel syndrome

Updated on 04 Aug 2024. Study ID: 844856

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A multicenter double-blind randomized placebo-controlled trial to evaluate the efficacy and safety of apraglutide in adult subjects with short bowel syndrome and intestinal failure (SBS-IF)

Brief description of study

Eligibility of study

Find a site

Interested in the study